Farasat Kazmi1, Yu Yang Soon1, Yiat Horng Leong1, Wee Yao Koh1, Balamurugan Vellayappan2,3. 1. Department of Radiation Oncology, National University Cancer Institute Singapore, National University Hospital, Singapore, 119228, Singapore. 2. Department of Radiation Oncology, National University Cancer Institute Singapore, National University Hospital, Singapore, 119228, Singapore. bala_vellayappan@nuhs.edu.sg. 3. Yong Loo Lin School of Medicine, National University of Singapore, 10 Medical Drive, Singapore, 117597, Singapore. bala_vellayappan@nuhs.edu.sg.
Abstract
PURPOSE: To determine the efficacy and toxicity of re-irradiation for patients with recurrent GBM. MATERIALS AND METHODS: We searched various biomedical databases from 1998 to 2018, for eligible studies where patients were treated with re-irradiation for recurrent GBM. Outcomes of interest were 6 and 12-month overall survival (OS-6, OS-12), 6 and 12-month progression free survival (PFS-6, PFS-12) and serious (Grade 3 +) adverse events (AE). We used the random effects model to pool outcomes across studies and compared pre-defined subgroups using interaction test. Methodological quality of each study was assessed using the Newcastle-Ottawa scoring system. RESULTS: We found 50 eligible non-comparative studies including 2095 patients. Of these, 42% were of good or fair quality. The pooled results were as follows: OS-6 rate 73% (95% confidence interval (CI) 69-77%), OS-12 rate 36% (95% CI 32-40%), PFS-6 rate 43% (95% CI 35-50%), PFS-12 rate 17% (95% CI 13-20%), and Grade 3 + AE rate 7% (95% CI 4-10%). Subgroup analysis showed that prospective studies reported higher toxicity rates, and studies which utilized brachytherapy to have a longer OS-12. Within the external beam radiotherapy group, there was no dose-response [above or below 36 Gy in 2 Gy equivalent doses (EQD2)]. However, a short fractionation regimen (≤ 5 fractions) seemed to provide superior PFS-6. CONCLUSION: The available evidence, albeit mostly level III, suggests that re-irradiation provides encouraging disease control and survival rates. Toxicity was not uniformly reported, but seemed to be low from the included studies. Randomized controlled trials (RCT) are needed to establish the optimal management strategy for recurrent GBM.
PURPOSE: To determine the efficacy and toxicity of re-irradiation for patients with recurrent GBM. MATERIALS AND METHODS: We searched various biomedical databases from 1998 to 2018, for eligible studies where patients were treated with re-irradiation for recurrent GBM. Outcomes of interest were 6 and 12-month overall survival (OS-6, OS-12), 6 and 12-month progression free survival (PFS-6, PFS-12) and serious (Grade 3 +) adverse events (AE). We used the random effects model to pool outcomes across studies and compared pre-defined subgroups using interaction test. Methodological quality of each study was assessed using the Newcastle-Ottawa scoring system. RESULTS: We found 50 eligible non-comparative studies including 2095 patients. Of these, 42% were of good or fair quality. The pooled results were as follows: OS-6 rate 73% (95% confidence interval (CI) 69-77%), OS-12 rate 36% (95% CI 32-40%), PFS-6 rate 43% (95% CI 35-50%), PFS-12 rate 17% (95% CI 13-20%), and Grade 3 + AE rate 7% (95% CI 4-10%). Subgroup analysis showed that prospective studies reported higher toxicity rates, and studies which utilized brachytherapy to have a longer OS-12. Within the external beam radiotherapy group, there was no dose-response [above or below 36 Gy in 2 Gy equivalent doses (EQD2)]. However, a short fractionation regimen (≤ 5 fractions) seemed to provide superior PFS-6. CONCLUSION: The available evidence, albeit mostly level III, suggests that re-irradiation provides encouraging disease control and survival rates. Toxicity was not uniformly reported, but seemed to be low from the included studies. Randomized controlled trials (RCT) are needed to establish the optimal management strategy for recurrent GBM.
Authors: Anita Mahajan; Ian E McCutcheon; Dima Suki; Eric L Chang; Samuel J Hassenbusch; Jeffrey S Weinberg; Almon Shiu; Moshe H Maor; Shiao Y Woo Journal: J Neurosurg Date: 2005-08 Impact factor: 5.115
Authors: Timothy A Chan; Jon D Weingart; Michele Parisi; Michael A Hughes; Alessandro Olivi; Scott Borzillary; Dineli Alahakone; Nicholas A Detorie; Moody D Wharam; Lawrence Kleinberg Journal: Int J Radiat Oncol Biol Phys Date: 2005-07-15 Impact factor: 7.038
Authors: S Patel; J C Breneman; R E Warnick; R E Albright; W D Tobler; H R van Loveren; J M Tew Journal: Neurosurgery Date: 2000-05 Impact factor: 4.654
Authors: Jean Marc Simon; Philippe Cornu; Gilbert Boisserie; Dominique Hasboun; Bernadette Tep; Claire Hardiman; Charles A Valery; Jean Yves Delattre; Didier Dormont; François Baillet; Jean Jacques Mazeron Journal: Int J Radiat Oncol Biol Phys Date: 2002-05-01 Impact factor: 7.038
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: David A Larson; Jeffrey M Suplica; Susan M Chang; Kathleen R Lamborn; Michael W McDermott; Penny K Sneed; Michael D Prados; William M Wara; M Kelly Nicholas; Mitchel S Berger Journal: Neuro Oncol Date: 2004-04 Impact factor: 12.300
Authors: C O Scharfen; P K Sneed; W M Wara; D A Larson; T L Phillips; M D Prados; K A Weaver; M Malec; P Acord; K R Lamborn Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: Andrés F Cardona; Daniel Jaramillo-Velásquez; Alejandro Ruiz-Patiño; Carolina Polo; Enrique Jiménez; Fernando Hakim; Diego Gómez; Juan Fernando Ramón; Hernando Cifuentes; Juan Armando Mejía; Fernando Salguero; Camila Ordoñez; Álvaro Muñoz; Sonia Bermúdez; Nicolas Useche; Diego Pineda; Luisa Ricaurte; Zyanya Lucia Zatarain-Barrón; July Rodríguez; Jenny Avila; Leonardo Rojas; Elvira Jaller; Carolina Sotelo; Juan Esteban Garcia-Robledo; Nicolas Santoyo; Christian Rolfo; Rafael Rosell; Oscar Arrieta Journal: J Neurooncol Date: 2021-09-09 Impact factor: 4.130
Authors: Tugce Kutuk; Ranjini Tolakanahalli; Nicole C McAllister; Matthew D Hall; Martin C Tom; Muni Rubens; Haley Appel; Alonso N Gutierrez; Yazmin Odia; Alexander Mohler; Manmeet S Ahluwalia; Minesh P Mehta; Rupesh Kotecha Journal: Cancers (Basel) Date: 2022-06-15 Impact factor: 6.575
Authors: T Gupta; M Maitre; P Maitre; J S Goda; R Krishnatry; A Chatterjee; A Moiyadi; P Shetty; S Epari; A Sahay; V Patil; R Jalali Journal: Clin Transl Oncol Date: 2021-02-02 Impact factor: 3.405
Authors: Daniel P Kulinich; John P Sheppard; Thien Nguyen; Aditya M Kondajji; Ansley Unterberger; Courtney Duong; Adam Enomoto; Kunal Patel; Isaac Yang Journal: Acta Neurochir (Wien) Date: 2021-04-02 Impact factor: 2.216
Authors: Joseph H McAbee; Charlotte Degorre-Kerbaul; Kristin Valdez; Astrid Wendler; Uma T Shankavaram; Colin Watts; Kevin Camphausen; Philip J Tofilon Journal: J Neurooncol Date: 2020-10-15 Impact factor: 4.130
Authors: Martin Kocher; Christiane Jockwitz; Philipp Lohmann; Gabriele Stoffels; Christian Filss; Felix M Mottaghy; Maximilian I Ruge; Carolin Weiss Lucas; Roland Goldbrunner; Nadim J Shah; Gereon R Fink; Norbert Galldiks; Karl-Josef Langen; Svenja Caspers Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639